Published in Aliment Pharmacol Ther on February 01, 2005
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41
TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol (2007) 2.17
How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol (2010) 1.48
Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut (2006) 1.24
Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol (2012) 1.16
Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol (2006) 1.11
Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol (2006) 1.06
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis. Front Immunol (2015) 0.92
Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci (2008) 0.92
Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis. Arthritis Res Ther (2008) 0.86
Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One (2012) 0.86
Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86
Adalimumab for the treatment of Crohn's disease. Biologics (2008) 0.86
Are biological agents toxic to human chondrocytes and osteocytes? J Orthop Surg Res (2015) 0.85
The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4⁺CD25⁺ regulatory T cells. Rheumatol Int (2012) 0.83
Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients. Clin Vaccine Immunol (2011) 0.82
Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol (2015) 0.81
Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. PLoS One (2016) 0.81
IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol (2015) 0.80
Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int (2014) 0.80
Adalimumab in Crohn's disease. Biologics (2007) 0.80
Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol (2010) 0.79
Is adalimumab protective in ischemia-reperfusion injury in lung? Iran J Basic Med Sci (2015) 0.78
Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol (2014) 0.78
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther (2013) 0.77
Molecular modeling of antibodies for the treatment of TNFα-related immunological diseases. Pharmacol Res Perspect (2016) 0.76
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol (2016) 0.76
Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics (2007) 0.75
In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut (2007) 0.75
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol (2016) 0.75
New biologics in the management of Crohn's disease: focus on certolizumab pegol. Clin Exp Gastroenterol (2009) 0.75
Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects. PLoS One (2016) 0.75
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology (1977) 2.79
Non-alcoholic duct destructive chronic pancreatitis. Gut (1997) 2.79
Appendectomy protects against ulcerative colitis. Gastroenterology (1994) 2.71
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
Microscopic colitis with giant cells. Histopathology (2002) 2.64
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 2.46
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
[Management and choice of antibiotics for patients with an allergy to penicillin]. Ned Tijdschr Geneeskd (1999) 2.02
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
OLGA staging for gastritis: a tutorial. Dig Liver Dis (2008) 1.64
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy (2001) 1.60
CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev (1996) 1.60
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Immunopathology of trachomatous conjunctivitis. Br J Ophthalmol (1989) 1.59
Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy (2008) 1.56
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut (1999) 1.55
European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis (2013) 1.53
Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3. J Immunol (1986) 1.52
Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax (2006) 1.50
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet (1990) 1.49
Influence of nutritional substrates on the formation of volatiles by the fecal flora. Gastroenterology (1991) 1.45
IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol (2000) 1.45
Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut (1995) 1.42
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr (1999) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects. Clin Exp Immunol (1995) 1.40
Controlled trial of YAG laser treatment of upper digestive hemorrhage. Gastroenterology (1982) 1.39
Helicobacter pylori infection and growth delay in older children. Arch Dis Child (1997) 1.39
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. Aliment Pharmacol Ther (2007) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut (1985) 1.38
Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther (2013) 1.37
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther (2005) 1.34
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther (2004) 1.33
Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther (2013) 1.32
Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology (2003) 1.31
Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut (2003) 1.31
Collagenous colitis: an abnormal collagen table? Two new cases and review of the literature. Am J Gastroenterol (1982) 1.30
Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol (1993) 1.29
Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr (1993) 1.29
Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut (1997) 1.26
Alveolar T-cell subsets in pulmonary sarcoidosis. Correlation with disease activity and effect of steroid treatment. Am Rev Respir Dis (1984) 1.26
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut (1996) 1.25
Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. J Immunol Methods (1990) 1.23
A new approach to the validation of tissue microarrays. J Pathol (2006) 1.23